Iqvia Holdings (IQV) Non Operating Interest Expenses (2012 - 2026)
Iqvia Holdings' (IQV) quarterly Non Operating Interest Expenses came in at $197.0 million in Q2 2026, up 8.24% year-over-year from $182.0 million in Q2 2025, and up 2.6% quarter-over-quarter from $192.0 million in Q1 2026.
Analysis
Iqvia Holdings (IQV) Non Operating Interest Expenses (2012 - 2026) Analysis & Trends
Iqvia Holdings has disclosed Non Operating Interest Expenses across 15 years of filings, most recently posting $197.0 million for Q2 2026.
- In Q2 2026, Non Operating Interest Expenses rose 8.24% year-over-year to $197.0 million; the TTM figure through Jun 2026 stood at $771.0 million (up 12.06% YoY), while the FY2025 annual figure was $729.0 million, up 8.81% from the prior year.
- Non Operating Interest Expenses came in at $197.0 million for Q2 2026 at Iqvia Holdings, up from $192.0 million in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $197.0 million in Q2 2026 to a low of $86.0 million in Q1 2022.
- Average Non Operating Interest Expenses over 5 years is $159.8 million, with a median of $169.5 million recorded in 2023.
- Year-over-year, Non Operating Interest Expenses slipped 13.13% in 2022 and soared 79.79% in 2023.
- Over 5 years, Non Operating Interest Expenses stood at $128.0 million in 2022, then jumped by 41.41% to $181.0 million in 2023, then decreased by 5.52% to $171.0 million in 2024, then climbed by 12.87% to $193.0 million in 2025, then grew by 2.07% to $197.0 million in 2026.
- Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $197.0 million in Q2 2026, $192.0 million in Q1 2026, and $193.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 197.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -48.79 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 30.34 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | - |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | 4,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 197.00 Mn |
| Mar 31, 2026 | 192.00 Mn |
| Dec 31, 2025 | 193.00 Mn |
| Sep 30, 2025 | 189.00 Mn |
| Jun 30, 2025 | 182.00 Mn |
| Mar 31, 2025 | 165.00 Mn |
| Dec 31, 2024 | 171.00 Mn |
| Sep 30, 2024 | 170.00 Mn |
| Jun 30, 2024 | 163.00 Mn |
| Mar 31, 2024 | 166.00 Mn |
| Dec 31, 2023 | 181.00 Mn |
| Sep 30, 2023 | 181.00 Mn |
| Jun 30, 2023 | 169.00 Mn |
| Mar 31, 2023 | 141.00 Mn |
| Dec 31, 2022 | 128.00 Mn |
| Sep 30, 2022 | 108.00 Mn |
| Jun 30, 2022 | 94.00 Mn |
| Mar 31, 2022 | 86.00 Mn |
| Dec 31, 2021 | 90.00 Mn |
| Sep 30, 2021 | 92.00 Mn |